Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis

Company Overview

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $13.26 to $15.35
• 50-Day Range: $13.60 to $17.07
• 52-Week Range: $6.20 to $18.68
• Volume: 51,728 shs
• Average Volume: 84,991 shs
• Market Capitalization: $17.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PIRS Stock Analysis - Frequently Asked Questions

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) released its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($19.20) earnings per share for the quarter, hitting analysts' consensus estimates of ($19.20). The biotechnology company had revenue of $4.06 million for the quarter, compared to analysts' expectations of $7.98 million. Pieris Pharmaceuticals had a negative net margin of 39.71% and a negative trailing twelve-month return on equity of 80.93%.

When did Pieris Pharmaceuticals' stock split?

Pieris Pharmaceuticals's stock reverse split before market open on Tuesday, April 23rd 2024.The 1-80 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Pieris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pieris Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Adobe (ADBE), GE Aerospace (GE) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 7/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PIRS
• CIK: 1583648
• Web: www.pieris.com
• Phone: (857) 246-8998
• Fax: 49-8161-141-1444
• Employees: 140
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($12.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.54 million
• Net Margins: -39.71%
• Pretax Margin: -1,179.96%
• Return on Equity: -80.93%
• Return on Assets: -59.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.82
• Quick Ratio: 4.82

Sales & Book Value

• Annual Sales: $42.81 million
• Price / Sales: 0.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $21.66 per share
• Price / Book: 0.63

Miscellaneous

• Outstanding Shares: 1,320,000
• Free Float: 1,236,000
• Market Cap: $17.95 million
• Optionable: Optionable
• Beta: 0.61